KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $538.6 million.

  • Travere Therapeutics' Liabilities and Shareholders Equity rose 677.44% to $538.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 1081.25%. This contributed to the annual value of $594.1 million for FY2024, which is 2469.07% down from last year.
  • Per Travere Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $538.6 million for Q3 2025, which was up 677.44% from $555.3 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $832.8 million for Q3 2023, and its period low was $504.4 million during Q3 2024.
  • Its 5-year average for Liabilities and Shareholders Equity is $694.3 million, with a median of $736.4 million in 2023.
  • Per our database at Business Quant, Travere Therapeutics' Liabilities and Shareholders Equity surged by 3332.65% in 2021 and then crashed by 3943.57% in 2024.
  • Quarter analysis of 5 years shows Travere Therapeutics' Liabilities and Shareholders Equity stood at $776.6 million in 2021, then decreased by 13.4% to $672.6 million in 2022, then rose by 17.3% to $788.9 million in 2023, then dropped by 24.69% to $594.1 million in 2024, then decreased by 9.35% to $538.6 million in 2025.
  • Its last three reported values are $538.6 million in Q3 2025, $555.3 million for Q2 2025, and $548.8 million during Q1 2025.